Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + Lenvima
pembrolizumab with lenvatinib · Merck / Eisai
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of adults with advanced renal cell carcinoma.
LAMPGEN ANALYSIS
Why it matters
The combination adds an immune checkpoint inhibitor and VEGF-targeted oral therapy as a first-line option.
What research teams should watch
Track infusion visits and oral dose interruptions together and reconcile attribution of hypertension and other events.
PRIMARY RECORDS